On Monday, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released topline results from Part 2 of a Phase 1/2 study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic ...
Corrections & Clarifications: Information about the phosphorous levels expected in a man-made lake was added to this article, and the headline was updated. Executives with Arrowhead Country Club ...